5:51 PM
 | 
Jun 06, 2019
 |  BC Innovations  |  Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

How Alexandria became the most prolific life sciences VC

Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down.

Over its 25-year history, Alexandria Real Estate Equities Inc. has built a life sciences real estate empire by anticipating the growth and infrastructure needs of the biotech and tech sectors, buying up property and developing office and lab spaces in hubs such as Boston, San Francisco, San Diego, Seattle and Research Triangle Park in North Carolina.

The strategy has produced an S&P 500 company with a market cap of more than $16 billion and total 2018 revenues of $1.3 billion.

The firm’s history of making venture investments in biotech dates back to at least 2001.

In the last 18 months Alexandria has ramped up its pace of dealmaking to become the most active venture investor in biotech.

But in the last 18 months Alexandria has ramped up its pace of dealmaking to become the most active venture investor in biotech, via its VC arm Alexandria Venture Investments, positioning the firm as a major player in life science investments, and giving it a foothold in emerging areas of science and some of the hottest new companies.

Since the start of 2018, Alexandria has participated in 46 venture financings for 44 life science companies -- over 50% more than the next most active VC, Arch Venture Partners, over the same period.

That’s also almost half the entire number of investments it made over the prior 22 years.

From 1996 to 2018, Alexandria invested in 96 venture financings, 28 of which came in 2017, 16 in 2016 and 16 between 2011 and 2015, according to BioCentury’s BCIQ database.

Moreover, Alexandria has been participating in deals where the portfolio companies are raising serious money.

Total money raised in deals...

Read the full 1526 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >